Physician profile
John Wehry
NPI 1174986046
$3,109.94
in general payments reported to CMS, 2019-2025
21 companies · $535 in 2025
The $535 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $342 · 2021: $257 · 2022: $405 · 2023: $618 · 2024: $767 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $530.74 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $500.54 | 2022-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $425.57 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $316.07 | 2020-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $214.11 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $153.52 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Sanofi Pasteur INC. | $152.30 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $136.07 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $130.25 | 2020-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Adlon Therapeutics L.P. | $94.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $81.18 | 2024-2025 | |
| Cranial Technologies, INC | $79.16 | 2023-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $79.02 | 2019-2021 | |
| Kaleo, INC. | $53.20 | 2020-2023 | Auvi-Q |
| Seqirus USA INC | $38.51 | 2024 | Flucelvax |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $37.78 | 2020 | |
| Pfizer INC. | $20.05 | 2025 | |
| Circassia INC. | $18.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.68 | 2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $16.16 | 2024 | Relexxii |
| Genentech USA, INC. | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wehry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.